Cardiac dilatation and pump dysfunction without intrinsic myocardial systolic failure following chronic

Oleg E Osadchii1, Gavin R Norton, Richard McKechnie

  • 1Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, University of the Witwatersrand, Johannesburg, Parktown, 2193, Johannesburg, South Africa.

Insights

Chronic sympathetic stimulation causes heart pump dysfunction primarily through left ventricular (LV) dilatation, not intrinsic systolic failure, despite cardiomyocyte damage and reduced beta-adrenoreceptor response.

Area of Science:

  • Cardiovascular Physiology
  • Heart Failure Pathophysiology
  • Pharmacology

Background:

  • Left ventricular (LV) pump dysfunction in dilated cardiomyopathy is poorly understood.
  • The relative contributions of chamber dilatation versus intrinsic systolic failure remain unclear.

Purpose of the Study:

  • To investigate whether LV pump dysfunction stems from chamber dilatation or intrinsic systolic failure.
  • To elucidate the mechanisms underlying heart pump dysfunction induced by chronic sympathetic stimulation.

Main Methods:

  • Rats received isoproterenol (a beta-adrenoreceptor agonist) for 3 months.
  • Evaluated LV pump function using echocardiography and isolated heart preparations.
  • Assessed cardiomyocyte damage, adrenergic receptor function, and LV hypertrophy.

Main Results:

  • Isoproterenol induced LV pump dysfunction and chamber dilatation.
  • Despite cardiomyocyte damage and beta-adrenoreceptor downregulation, intrinsic myocardial contractility remained preserved.
  • Compensatory mechanisms included increased norepinephrine release and LV hypertrophy.
  • LV pump failure was primarily linked to LV dilatation.

Conclusions:

  • Chronic sympathetic stimulation induces heart pump dysfunction mainly via LV dilatation.
  • Intrinsic myocardial systolic function is preserved despite myocyte damage and altered beta-adrenergic responses.
  • LV dilatation, not intrinsic systolic failure, is the primary driver of pump dysfunction in this model.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...